Basilea Pharmaceutica
Trial Pipeline
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
NCT06733675
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
NCT05582187
Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants
NCT05527834
A Bioequivalence Study of APX001 High-load and Low-load Tablets
NCT05491733
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
NCT04045613
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
NCT03137173
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
NCT01752920
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 3 | 3 |
What the Pipeline for Basilea Pharmaceutica Shows
According to the ClinicalTrials.gov registry, Basilea Pharmaceutica is linked to 9 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting — about 33% of the sponsor's indexed portfolio — and 6 are already marked complete, representing roughly 67% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Basilea Pharmaceutica reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 6 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Basilea Pharmaceutica is Pharmacokinetics with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.